Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder.

Autor:	Eidelberg D; The Feinstein Institutes for Medical Research., Tang C; The Feinstein Institutes for Medical Research., Nakano Y; The Feinstein Institutes for Medical Research., Vo A; The Feinstein Institutes for Medical Research., Nguyen N; Albert Einstein College of Medicine., Schindlbeck K; The Feinstein Institutes for Medical Research., Poston K; Stanford University., Gagnon JF; Université du Québec à Montréal., Postuma R; McGill University., Niethammer M; The Feinstein Institutes for Medical Research., Ma Y; Center for Neurosciences, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York, USA., Peng S; Center for Neurosciences, Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, New York, USA., Dhawan V; The Feinstein Institutes for Medical Research.
Jazyk:	angličtina
Zdroj:	Research square [Res Sq] 2024 May 28. Date of Electronic Publication: 2024 May 28.
DOI:	10.21203/rs.3.rs-4427198/v1
Abstrakt:	Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal syndrome for Parkinson's disease (PD) and related α -synucleinopathies. We conducted a longitudinal imaging study of network changes in iRBD and their relationship to phenoconversion. Expression levels for the PD-related motor and cognitive networks (PDRP and PDCP) were measured at baseline, 2 and 4 years, along with dopamine transporter (DAT) binding. PDRP and PDCP expression increased over time, with higher values in the former network. While abnormal functional connections were identified initially within the PDRP, others bridging the two networks appeared later. A model based on the rates of PDRP progression and putamen dopamine loss predicted phenoconversion within 1.2 years in individuals with iRBD. In aggregate, the data suggest that maladaptive reorganization of brain networks takes place in iRBD years before phenoconversion. Network expression and DAT binding measures can be used together to assess phenoconversion risk in these individuals. Competing Interests: Additional Declarations: There is NO Competing Interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu